Scientific Reports Research Articles

Cancer Vaccine Therapy Using Carcinoembryonic Antigen – expressing Dendritic Cells Generated from Induced Pluripotent Stem Cells

Junya Kitadani<sup>1</sup>, Toshiyasu Ojima<sup>1</sup>, Hiromitsu Iwamoto<sup>1</sup>, Hirotaka Tabata<sup>1</sup>, Mikihito Nakamori<sup>1</sup>, Masaki Nakamura<sup>1</sup>, Keiji Hayata<sup>1</sup>, Masahiro Katsuda<sup>1</sup>, Masayasu Miyajima<sup>2</sup> and Hiroki Yamaue<sup>1</sup>

 <sup>1</sup> Second Department of Surgery, Wakayama Medical University, School of Medicine, Wakayama 641-8510, Japan
<sup>2</sup> Laboratory Animal Center, Wakayama Medical University, School of Medicine, Wakayama 641-8510, Japan (a)



Maturation stability of hiPSDCs by other maturation factors. (a) Surface phenotypes of hiPSDCs matured by other representative maturation factors (rhTNF $\alpha$ , lipopolysaccharide [LPS], OK432, polyinosinic-polycytidylic acid [PolyI:C]). Histograms show the staining patterns of specific antibodies (black) and isotype-matched controls (thin lines). (b) Secretion of IFN- $\gamma$  and IL-12 (p70) from hiPSDCs matured by other representative maturation factors (rhTNF $\alpha$ , LPS, OK432, PolyI:C). Data are mean  $\pm$  SD (three donors for each group).